• -
  • English
  • Japanese
  • Korean
市場調查報告書
商品編碼
949499

糖尿病治療藥的全球市場:2020年∼2026年

Diabetes Care Drugs Market 2020-2026
出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

糖尿病治療藥市場，在預測期間內預計穩定成長。市場成長的促進因素，是糖尿病的患病人數劇增。

本報告提供全球糖尿病治療藥市場相關調查分析，市場概要，各市場區隔的市場分析，各地區的市場分析，競爭情形，主要企業等相關的系統性資訊。

目錄

第1章 報告摘要

第2章 市場概要與考察

  • 報告的範圍
  • 分析師的考察和目前市場趨勢
  • 法律規章

第3章 競爭情形

  • 主要企業分析
    • Novo Nordisk A/S
    • Sanofi SA
    • AstraZeneca PLC
    • Eli Lilly and Co.
    • Boehringer Ingelheim International GmbH
  • 主要策略分析

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 機會

第5章 市場區隔

  • 全球糖尿病治療藥市場:各藥物分類
    • 胰島素
    • 非胰島素注射藥
    • 口服抗糖尿病藥物
    • 並用藥

第6章 各地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他的亞太地區
  • 其他地區

第7章 企業簡介

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bausch Health Companies Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • Generex Biotechnology Corp.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Midatech Pharma Plc
  • Mylan NV
  • Novartis International AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceuticals Co.Ltd.
  • Teva Pharmaceuticals Industries Ltd.
目錄
Product Code: OMR2021818

Global Diabetes Care Drugs Market Size, Share & Trends Analysis Report by Drug Class (Insulins, Non-Insulin Injectable Drugs, Oral Anti-Diabetic Drugs, and Combination Drugs), and Forecast, 2020-2026

The global diabetes care drug market is projected to grow at a steady CAGR during the forecast period. The primary factors that are driving the growth of the global diabetes care drugs industry include the rising prevalence of diabetes amongst the peoples across the globe. Further, the rising level of stress, changing lifestyles, excessive consumption of alcohol, smoking, and other junk food consumption that elevated the body's sugar levels further leads to the development of diabetes among people and hence create demand for drugs to treat the disease. In addition, advancements in drug manufacturing along with the availability of fast-acting drugs also fuel the market growth during the forecast period. However, the availability of alternative products such as diabetes care devices serves as a restricting factorforthe growth of the market.

The global diabetes care drugs market is segmented on the basis of drug class as insulins, non-insulin injectable drugs, oral anti-diabetic drugs, and combination drugs. Insulins are amongst the most consumed and favored drug, owing to its fast- and long-action properties. Based on the geographic viewpoint, the global diabetes care drugs market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to hold a considerable share in the market. Asia-Pacific is estimated to exhibit a significant growth rate in the market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Boehringer Ingelheim International GmbH, Sanofi SA, Novo Nordisk A/S, Eli Lilly and Co., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Co., Johnson & Johnson Services Inc., Novartis International AG, Pfizer Inc., and Takeda Pharmaceuticals Co.Ltd., are some of the prominent players operatingin the global diabetes care drugs market. In March 2019, Novo Nordisk announced its plan to invest around$98 million in upgrading and expanding the insulin drug manufacturing facility in Kalundborg, Denmark. Such efforts by the players provide an opportunity for the future growth of the market as well as enable the market players to gain maximum share in the market.

Research Methodology

The market study of the global diabetes care drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for diabetes care drugmanufacturers, drug manufacturing companies, raw material suppliers, distributors, active pharmaceutical ingredient manufacturers, contract research organizations, contract manufacturers, investing companies, industry associations &experts, research institutes,government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Diabetes Care Drugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global diabetes care drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global diabetes care drug market.
  • Insights about market determinants which are stimulating the global diabetes care drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Novo Nordisk A/S
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Sanofi SA
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. AstraZeneca PLC
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Eli Lilly and Co.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Boehringer Ingelheim International GmbH
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Diabetes CareDrugs Market by Drug Class
    • 5.1.1. Insulins
    • 5.1.2. Non-Insulin Injectable Drugs
    • 5.1.3. Oral Anti-Diabetic Drugs
    • 5.1.4. Combination Drugs

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Astellas Pharma Inc.
  • 7.2. AstraZeneca Plc
  • 7.3. Bayer AG
  • 7.4. Bausch Health Companies Inc.
  • 7.5. Biocon Ltd.
  • 7.6. Boehringer Ingelheim International GmbH
  • 7.7. Bristol Myers Squibb Co.
  • 7.8. Eli Lilly and Co.
  • 7.9. Generex Biotechnology Corp.
  • 7.10. Johnson & Johnson Services Inc.
  • 7.11. Merck & Co. Inc.
  • 7.12. Midatech Pharma Plc
  • 7.13. Mylan NV
  • 7.14. Novartis International AG
  • 7.15. Novo Nordisk A/S
  • 7.16. Oramed Pharmaceuticals Inc.
  • 7.17. Pfizer Inc.
  • 7.18. Sanofi SA
  • 7.19. Takeda Pharmaceuticals Co.Ltd.
  • 7.20. Teva Pharmaceuticals Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 2. GLOBAL INSULINS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL NON-INSULIN INJECTABLE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ORAL ANTI-DIABETIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL COMBINATION DRUGS FOR DIABETES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 7. NORTH AMERICAN DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 8. NORTH AMERICAN DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 9. EUROPEAN DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 10. EUROPEAN DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 11. ASIA-PACIFIC DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 12. ASIA-PACIFIC DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 13. REST OF THE WORLD DIABETES CARE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL DIABETES CARE DRUGS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
  • 2. GLOBAL DIABETES CARE DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 3. US DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF THE WORLD DIABETES CARE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)